

## IMPROVED NEUROPROTECTION WITH MELATONIN-AUGMENTED HYPOTHERMIA VS HYPOTHERMIA ALONE IN A PERINATAL ASPHYXIA MODEL: A RANDOMIZED STUDY

E. Powell<sup>1</sup>, S. Faulkner<sup>1</sup>, A. Bainbridge<sup>2</sup>, A. Kereyni<sup>1</sup>, D. Kelen<sup>1</sup>, M. Chandrasekaran<sup>1</sup>, L. Lecky-Thompson<sup>1</sup>, D. Price<sup>2</sup>, E. Cady<sup>2</sup>, G. Raivich<sup>1</sup>, X. Golay<sup>3</sup>, N.J. Robertson<sup>1</sup>

<sup>1</sup>Institute for Women's Health, University College London, <sup>2</sup>Medical Physics and Bioengineering, UCLH NHS Foundation Trust, <sup>3</sup>Institute of Neurology, University College London, London, UK

**Background:** Melatonin (N-acetyl-5-methoxytryptamine) is a naturally occurring hormone, anti-oxidant and cellular pro-survival factor, used safely in children with sleep disorders. Melatonin is beneficial following brain injury in adult animals. It is unknown if melatonin augments hypothermic neuroprotection in the developing brain.

**Aims:** To assess the neuroprotective efficacy of melatonin combined with cooling to 33.5°C in a piglet model of perinatal asphyxia.

**Methods:** Seventeen anaesthetised male piglets, < 24h old, underwent transient hypoxia-ischaemia (HI), then were cooled to 33.5°C 2-26h after HI and randomised to i) hypothermia alone (n=8); or ii) hypothermia+melatonin (5mg/kg infused over 6h starting 10 min after HI and repeated at 24h, n=9). Cortical white matter (WM) and ventromedial forebrain (vmFB) proton (1H) and forebrain (FB) were obtained at baseline, and 24 and 48h following HI.

**Results:** Compared to hypothermia alone, melatonin and hypothermia significantly decreased the areas under the post HI time-series curves for vmFB lactate (Lac)/N-acetylaspartate (NAA) and Lac/creatine (Cr) ( $p < 0.05$ ); as well as reducing the drop in WM NAA/Cr ( $p < 0.05$ ) (Fig1). Heart rate, mean arterial blood pressure and inotrope use did not differ between groups.

**Conclusions:** Validated MRS biomarkers suggested cooling plus melatonin augmented hypothermic neuroprotection in both vmFB and WM. Melatonin is a promising candidate for clinical trials of neuroprotection in the future.




Fig 1: VmFB and WM 1H metabolite-ratio areas under the curves (AUC) 48 h post HI. Yellow: cooling only; blue cooling plus melatonin. Cho - choline. (\* $p < 0.05$  two sided t-test)

[figure 1]

**Funding:** Wellbeing of Women, grant number RG952